Pacira BioSciences, Inc.

PCRX · Moat type: REGULIERUNG

MoatScore

2/10

Fair Value

19 USD

Margin of Safety

-32.3 %

Rating

MEIDEN

Pacira BioSciences develops and markets non-opioid-based pain therapies – primarily based on its liposomal bupivacaine technology – which are sold directly to hospitals and surgical centers and used in perioperative pain management.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.